Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gevokizumab in Pyoderma Gangrenosum
NCT02315417Phase 3Terminated
- Sponsor
- XOMA
- Start
- Nov 2014
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gevokizumab in pyoderma gangrenosum (PG) (3 arms), sponsored by XOMA. Primary endpoint: Proportion of subjects with complete closure of the PG target ulcer at Day 126. Started Nov 2014; status: terminated.
02
Drugs
gevokizumab
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT02315417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02315417.